“Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s66, https://doi.org/10.25251/skin.5.supp.66.